Colorectal disease
Conditions
Interventions
liposomal bupivacaine group (LB group):0.65% liposomal bupivacaine 20ml will be used for quadratus lumborum block.
Ropivacaine group (R group):0.2% ropivacaine 20ml will be used for quadratus lumborum block.
Sponsors
Peking University Shenzhen Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: Age 18-90 years old; Both men and women; ASA GradeI-III; BMI<40kg/m²; Patients who are undergoing colorectal surgery under general anesthesia and have signed informed consent.
Exclusion criteria
Exclusion criteria: Coagulation abnormalities, infection/inflammation at the puncture site, allergy to liposomal bupivacaine or ropivacaine, a clear or known history of spinal deformation or spinal surgery, and a history of chronic pain, patients with intestinal obstruction, refused to sign the informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| First postoperative exhaust time; | — |
Secondary
| Measure | Time frame |
|---|---|
| Intake, feeling nauseated, emesis, exam, and duration of symptoms scoring system (I-FEED) score;Incidence of postoperative gastrointestinal dysfunction (POGD);visual analogue scale (VAS) score of pain at rest/activity;Additional doses of opioids;Occurrence and severity of postoperative nausea and vomiting (PONV);Type and dosage of additional antiemetic drugs;Time to get out of bed for the first time;Duration of postanesthesia care unit (PACU);Duration of postoperative length of stay (LOS); QOR-15 score during hospitalization; | — |
Countries
China
Contacts
Public ContactXinhai Wu
Peking University Shenzhen Hospital
Outcome results
None listed